BBR Partners LLC Grows Stock Position in Altimmune, Inc. (NASDAQ:ALT)

BBR Partners LLC boosted its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 374,784 shares of the company’s stock after acquiring an additional 16,271 shares during the quarter. BBR Partners LLC owned 0.53% of Altimmune worth $2,492,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in Altimmune by 1,150.9% in the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after purchasing an additional 3,959 shares during the period. Jump Financial LLC acquired a new position in shares of Altimmune during the 4th quarter worth about $120,000. Independent Advisor Alliance acquired a new stake in Altimmune in the 4th quarter worth about $112,000. Sectoral Asset Management Inc. purchased a new stake in Altimmune during the 4th quarter worth approximately $1,922,000. Finally, Lighthouse Investment Partners LLC purchased a new stake in shares of Altimmune during the fourth quarter worth $4,493,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. B. Riley restated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a report on Friday, June 21st. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. JMP Securities decreased their price objective on Altimmune from $25.00 to $24.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.80.

Insider Buying and Selling at Altimmune

In other news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares of the company’s stock, valued at $289,510.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.10% of the stock is currently owned by corporate insiders.

Altimmune Stock Down 1.7 %

ALT opened at $6.39 on Friday. Altimmune, Inc. has a 52 week low of $2.09 and a 52 week high of $14.84. The business has a fifty day simple moving average of $6.66 and a 200-day simple moving average of $7.70. The firm has a market cap of $453.06 million, a P/E ratio of -4.02 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. During the same period in the prior year, the company posted ($0.32) earnings per share. Sell-side analysts expect that Altimmune, Inc. will post -0.54 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.